查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1858039

藥物動力學服務市場：按類型、按服務類型、按最終用戶分類 - 全球預測 2025-2032

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物動力學服務市場規模將達到 24.3 億美元，複合年成長率為 9.26%。

關鍵市場統計數據
基準年 2024 11.9億美元
預計年份：2025年 13億美元
預測年份 2032 24.3億美元
複合年成長率 (%) 9.26%

本文概述了藥物動力學服務在現代藥物研發中的方法論基礎和戰略重要性。

藥物動力學服務是現代藥物發現和開發的重要支柱，它提供了連接分子特性與臨床結果的定量基礎。本導言將藥物動力學定義為一個交叉學科領域，它整合了分析化學、生物分析、建模和體內實驗，以表徵藥物的吸收、分佈、代謝和排泄過程。透過描述潛在治療藥物在生物系統中的行為，藥物動力學指南從臨床前到臨床階段的給藥策略、安全性評估和轉化決策。

隨著監管要求的提高和治療方法的多樣化，藥物動力學實驗室不斷擴展其能力，以支持傳統的小分子藥物和日益複雜的生技藥品。先進質譜技術、高通量生物分析工作流程以及基於生理的藥物動力學模型的融合，顯著提高了暴露-反應表徵的準確性。因此，從第一線科學家到專案負責人，組織中的相關人員都依賴及時且可重複的藥物動力學數據來降低專案風險、最佳化調查方法設計並為監管溝通提供資訊。本節將重點介紹該領域的方法論基礎、跨職能重要性以及營運壓力，為後續的詳細分析奠定基礎。

技術發展、治療方式多樣化以及監管預期正在再形成醫療服務提供者的能力和科學合作。

在技​​術進步、治療模式組合轉變和監管預期變化的推動下，藥物動力學服務格局正在改變。生物分析儀器的創新，例如質譜靈敏度的提高和自動化樣品處理，正在縮短週轉時間並擴大可可靠定量分析的化合物範圍。同時，生技藥品、基因療法藥物和核酸療法的興起，迫使服務供應商開發與標準小分子工作流程顯著不同的專用檢測和基質處理能力。

此外，建模和模擬技術已發展成熟，成為重要的策略決策支援工具。基於生理學和群體藥物動力學的模型現已被常規用於根據臨床前數據預測人體藥物動力學，選擇初始人體劑量，並模擬不同的給藥方案。同時，監管機構也越來越期望獲得整合的藥物動力學/藥效學分析和透明的建模報告，促使供應商將監管文件納入其交付成果中。這些轉變正在重塑供應商與客戶之間的關係，強調更深入的科學合作以及能夠適應不同治療模式和更短研發週期的靈活模組化服務。

2025年的關稅調整將給供應鏈帶來壓力，並造成跨境貿易的複雜性，因此營運韌性和籌資策略至關重要。

2025年美國關稅政策和貿易動態的變化將對藥物動力學服務生態系統產生多方面的影響。許多服務提供者依賴進口原料、專用試劑和高價值儀器零件。這些投入品關稅負擔的增加可能會增加採購的複雜性，並促使企業重新評估籌資策略。為因應此挑戰，各機構可以增加庫存儲備、篩選合格的替代供應商，或加入區域採購網路，以維持營運的連續性。

除了直接投入成本外，關稅引發的貿易摩擦還會影響跨境合作在設備維護、備件供應和樣品轉移等方面的進度。跨境營運的合約研究機構和分析實驗室可能面臨額外的海關文件和潛在的延誤，從而影響研究進度和客戶關係。重要的是，這些動態促使人們更加關注近岸外包和供應商多元化，將其作為應對策略。因此，策略採購、合約靈活性和物流已成為相關人員的優先事項，他們希望在維持藥物動力學分析所需科學嚴謹性的同時，減輕關稅相關干擾帶來的營運影響。

基於詳細細分的洞察揭示了不同產品類型、服務方式和客戶群的不同分析需求和交付模式。

細分市場分析揭示了跨產品類型、服務方式和最終用戶類別的服務開發和客戶參與路徑清晰可見。依產品類型分類，市場分為大分子藥物動力學服務和小分子藥物動力學服務。大分子需要開發免疫測量、配體結合分析以及專門的樣品處理技術來解決穩定性和基質效應問題，而小分子通常採用高解析度質譜和檢驗的層析法方法。按服務類型分類，市場分為體外和體內兩部分，顯示體外ADME和穩定性分析能夠補充體內藥物動力學研究，為早期候選化合物的選擇和清除途徑的機制理解提供資訊。按最終用戶分類，市場涵蓋學術和政府研究機構、生物技術公司、委外研發機構和製藥公司，表明客戶需求各不相同，從探索性的假設驅動研究到完全符合GLP規範且需提供完整監管申報文件的規範化研究，不一而足。

綜上所述，這些細分市場決定了服務提供者必須提供模組化服務方案，用於生技藥品的高靈敏度分析、小分子高通量平台以及針對最終用戶的特定交付成果。學術和政府研究機構通常優先考慮方法的靈活性和新型檢測方法的開發，而生物技術公司則需要敏捷性和科學夥伴關係，委外研發機構優先考慮可擴展的營運和合規性，大型製藥企業則需要整合的專案管理和符合監管要求的彙報。這種主導的觀點凸顯了可自訂的工作流程、強大的品質系統和適應性強的商業模式對於有效服務多元化客戶群的重要性。

區域競爭優勢和營運考量決定了藥物動力學服務供應商在全球的投資、合作和規模擴張方向。

區域動態正在塑造美洲、歐洲、中東和非洲以及亞太地區的服務產品、基礎設施投資和合作網路，每個地區都擁有獨特的競爭優勢和營運考量。在美洲，生技中心和臨床開發中心的高度集中支持了快速的轉化工作流程和緊密的醫病關係，而監管趨勢和支付方環境則影響著北美申辦者對臨床藥理學和資料包裝的重視程度。在歐洲、中東和非洲，監管體系的多元化和強大的學術研究合作促進了跨境合作、多中心研究和統一的檢測驗證，以滿足不同司法管轄區的要求。

在亞太地區，分析能力正不斷提升，這主要得益於實驗室基礎設施的投資以及合約研究能力的日益成長。這種成長有助於以經濟高效的方式執行日益複雜的大量生物分析和生技藥品業務。不同地區的物流、樣本轉移法規和本地人才庫各不相同，這些都會影響研究設計和外包決策。因此，有效的區域策略應結合客戶接近性、法規專業知識和供應鏈韌性，以提供一致、高品質的藥物動力學服務，同時支援全球專案執行和知識轉移。

競爭動態有利於那些整合了先進分析技術、跨產業專業知識和以客戶為中心的商業模式，並能建立長期夥伴關係關係的供應商。

主要企業正在從單純的交易型檢測服務轉型為提供涵蓋生物分析、建模和法規支援的綜合性科學夥伴關係。成功的公司透過投資平台自動化、數據完整性系統以及跨職能團隊來脫穎而出，這些團隊能夠將分析結果轉化為可操作的藥物動力學和動態解讀。與儀器製造商和軟體供應商建立策略聯盟可以提高分析靈敏度和通量，而內部開發的標準化報告範本則可以加快法規申報流程並促進客戶決策。

此外，各公司正投資培養分析化學家、臨床藥理學家和建模專家等人才，以提供端到端的專案支援。在商業性，彈性價格設定模式、捆綁式配套服務以及產能保障等措施，旨在滿足客戶的風險承受能力和研發時間表。能夠展現出持續高品質、透明的審核準備以及從早期發現到規範臨床試驗的擴展能力的供應商，最有可能與客戶建立長期夥伴關係。總之，競爭格局青睞那些兼具深厚科學實力、卓越營運和以客戶為中心的服務理念的機構。

服務供應商加強科學研究能力、營運韌性和以客戶為中心的商業性框架的實際策略重點

產業領導者應優先考慮切實可行的變革，以增強科學研究能力、商業性韌性和客戶契合度。首先，投資於平台自動化和穩健的生物分析工作流程可以加快週轉時間並提高可重複性。其次，拓展服務團隊的建模和模擬專業知識，可以幫助供應商提供預測性見解，進而指導劑量選擇和研究設計，為客戶專案增添策略價值。

第三，供應鏈多元化以及對多家試劑和設備供應商進行資格認證，可以降低貿易中斷和關稅相關影響帶來的風險。第四，制定靈活的合約架構和基於價值的定價機制，有助於使獎勵與客戶保持一致，尤其對於需要定期調整專案的生技公司和贊助模式更是如此。最後，加強監管支援服務，例如文件準備和清晰的建模報告，有助於客戶滿足多司法管轄區的申報要求。這些舉措共同提升了營運韌性，深化了科學合作，並將供應商定位為日益複雜的藥物研發路徑中不可或缺的合作夥伴。

採用透明的多方法調查方法，結合專家訪談、文獻綜合和情境分析，檢驗藥物動力學服務的趨勢和影響。

本分析的調查方法融合了定性專家訪談、主題文獻綜述以及對技術和監管趨勢的結構化評估。主要見解來自與藥物動力學科學家、臨床藥理學家、實驗室營運負責人和採購專家的對話，以確保對能力和限制因素有多方面的了解。次要研究包括同行評審出版物、監管指導文件和近期技術白皮書，以了解生物分析設備開發、建模方法和檢測驗證實踐的最新進展。

分析綜合強調對不同資訊來源的主題進行交叉檢驗，以識別一致的模式，而非孤立的觀察結果。在適用情況下，透過情境分析評估營運影響，以評估供應鏈敏感性和不斷變化的監管預期帶來的影響。在整個過程中，我們始終專注於確保方法論的透明度，記錄假設，並確定哪些領域需要進一步的實證研究，以利於專業的專案規劃和採購決策。

總結了供應商在藥物動力學服務中整合戰略要務，以協調科學創新、營運韌性和以客戶為中心的服務交付。

總之，藥物動力學服務在將分子發現轉化為安全有效的臨床策略方面發揮核心作用，該領域正在適應技術、模式和地緣政治方面的壓力。投資先進生物分析平台、擴展建模和模擬能力並建立穩健供應鏈的供應商將更有能力滿足學術贊助商、生物技術公司、委外研發機構和大型製藥公司的多樣化需求。此外，區域動態和關稅相關因素凸顯了靈活採購和近岸外包策略對於確保專案進度和資料品質的重要性。

展望未來，預測模型分析結果、監管導向文件和以客戶為中心的合約的緊密整合，很可能成為服務提供者差異化的關鍵所在。透過落實上述切實可行的建議，相關人員可以降低研發風險，加速轉換里程碑的達成，並使服務交付與策略專案目標保持一致。科學、營運和商業性部門之間的持續協作，對於維護藥物動力學服務生態系統的創新性和信譽至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧模型整合到早期藥物動力學建模中，以最佳化劑量選擇和預測人體藥物動力學
  • 利用加速器質譜技術進行微劑量臨床試驗以提高安全性和生物有效性分析的需求日益成長
  • 拓展客製化體外人類肝微粒體檢測服務，以支持精準醫療和藥物交互作用研究
  • 利用晶片器官和微生理系統進行生理相關的藥物動力學和毒性評估
  • 擴大群體藥物動力學建模軟體平台在癌症藥物研發的應用，以簡化給藥方案設計
  • 將整合的PK/PD成像和生物標記分析外包給CRO，以加速先導藥物最適化決策支援。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按類型分類的藥物動力學服務市場

  • 大分子藥物動力學服務
  • 小分子藥物動力學服務

9. 按服務類型分類的藥物動力學服務市場

  • 體外
  • 體內

第10章：依最終用戶分類的藥物動力學服務市場

  • 學術和政府研究機構
  • 生技公司
  • 受託研究機構
  • 製藥公司

第11章：按地區分類的藥物動力學服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：按組別分類的藥物動力學服務市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：各國藥物動力學服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Absorption Systems LLC
    • Allucent
    • Aurigene Pharmaceutical Services Ltd.
    • Certara
    • Charles River Laboratories, Inc.
    • Creative Bioarray
    • Eurofins Scientific SE
    • Evotec SE
    • Frontage Laboratories, Inc.
    • ICON PLC
    • Laboratory Corporation of America Holdings
    • LGC Limited by Cinven
    • NUVISAN Pharma Holding GmbH
    • Pacific BioLabs
    • Parexel International（MA）Corporation
    • Pfizer Inc.
    • PPD Inc. by Thermo Fisher Scientific Inc.
    • Premier Consulting
    • Reaction Biology Corporation
    • SGS SA
    • Svar Life Science AB
    • WuXi AppTec Co., Ltd.
    • XenoTech by BioIVT
    • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market is projected to grow by USD 2.43 billion at a CAGR of 9.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.19 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.26%

Foundational overview describing the methodological backbone and strategic importance of pharmacokinetics services across modern drug development

Pharmacokinetics services are an integral pillar of contemporary drug discovery and development, providing the quantitative backbone that links molecular properties to clinical outcomes. This introduction frames pharmacokinetics as a multidisciplinary discipline that synthesizes analytical chemistry, bioanalysis, modeling, and in vivo experimentation to characterize absorption, distribution, metabolism, and excretion profiles. By establishing how therapeutic candidates behave in biological systems, pharmacokinetics guides dosing strategies, safety assessments, and translational decision-making across preclinical and clinical stages.

As regulatory expectations rise and therapeutic modalities diversify, pharmacokinetics laboratories have expanded capabilities to support both traditional small molecules and increasingly complex biologics. The convergence of advanced mass spectrometry, high-throughput bioanalytical workflows, and physiologically based pharmacokinetic modeling has improved the precision of exposure-response characterization. Consequently, organizational stakeholders-from bench scientists to program leads-depend on timely, reproducible pharmacokinetic data to de-risk portfolios, optimize trial design, and inform regulatory interactions. This section sets the stage for the deeper analyses that follow by highlighting the methodological foundations, cross-functional importance, and operational pressures shaping services in this sector.

Evolving technology, modality diversity, and regulatory expectations reshaping provider capabilities and collaborative scientific engagement

The pharmacokinetics services landscape is undergoing transformative shifts driven by technological advances, changing modality mixes, and evolving regulatory expectations. Innovations in bioanalytical instrumentation, including increased sensitivity in mass spectrometry and automation of sample processing, are shortening turnaround times and expanding the range of compounds that can be robustly quantified. At the same time, the rise of biologics, gene therapies, and nucleic acid medicines has compelled service providers to develop specialized assays and matrix handling capabilities that differ markedly from standard small molecule workflows.

Moreover, modeling and simulation techniques have matured into strategic decision-support tools. Physiologically based and population pharmacokinetic models are now routinely used to predict human pharmacokinetics from preclinical data, guide first-in-human dose selection, and simulate alternative dosing regimens. In parallel, regulatory agencies increasingly expect integrated PK/PD analyses and transparent modeling reports, prompting providers to embed regulatory-ready documentation into their deliverables. Together, these shifts are reshaping provider-client relationships, prompting deeper scientific collaboration and a focus on flexible, modular service offerings that can accommodate diverse therapeutic modalities and accelerated development timelines.

Operational resilience and procurement strategies becoming critical as tariff changes in 2025 introduce supply chain pressure and cross-border complexities

Changes to tariff policies and trade dynamics in the United States during 2025 have exerted a multifaceted influence on the pharmacokinetics services ecosystem, primarily through supply chain and cost-channel effects rather than direct scientific impact. Many service providers rely on imported raw materials, specialized reagents, and high-value instrumentation components; incremental tariff burdens on these inputs can elevate procurement complexity and prompt re-evaluation of sourcing strategies. In response, organizations may increase inventory buffers, qualify alternative suppliers, or shift to regional procurement networks to preserve operational continuity.

Beyond direct input costs, tariff-driven trade frictions can affect timelines for equipment maintenance, the availability of spare parts, and cross-border collaboration on sample transfers. Contract research organizations and analytical laboratories that operate transnationally may face additional customs documentation and potential delays, which in turn influence study timelines and client relationships. Importantly, these dynamics encourage greater attention to nearshoring and supplier diversification as resilience strategies. As a result, strategic procurement, contractual flexibility, and enhanced logistics planning have become priorities for stakeholders aiming to mitigate the operational consequences of tariff-related disruptions while maintaining the scientific rigor required for pharmacokinetic analyses.

Detailed segmentation-driven insights revealing distinct analytical requirements and delivery models across product types, service approaches, and client profiles

Segmentation analysis reveals distinct pathways for service development and client engagement across product types, service modalities, and end-user categories. Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services, which highlights divergent analytical demands: large molecules require immunoassay development, ligand-binding assays, and specialized sample handling to address stability and matrix effects, whereas small molecules often leverage high-resolution mass spectrometry and validated chromatographic methods. Based on Service Type, market is studied across In-Vitro and In-Vivo, illustrating that in vitro ADME and stability assays complement in vivo pharmacokinetic studies by informing early candidate selection and mechanistic understanding of clearance pathways. Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, demonstrating that client needs vary from exploratory, hypothesis-driven investigations to fully regulated GLP-compliant studies with comprehensive documentation for regulatory submissions.

Taken together, these segmentation dimensions emphasize that providers must offer modular service stacks that accommodate high-sensitivity analytics for biologics, throughput-focused platforms for small molecules, and end-user-specific deliverables. Academic and government research institutes often prioritize methodological flexibility and novel assay development, biotechnology companies require agility and scientific partnership, contract research organizations focus on scalable operations and compliance, and large pharmaceutical companies demand integrated program management and regulatory-grade reporting. This segmentation-driven perspective underscores the necessity for customizable workflows, robust quality systems, and adaptable commercial models to serve a heterogeneous client base effectively.

Regional competitive advantages and operational considerations determining where pharmacokinetics service providers invest, collaborate, and scale globally

Regional dynamics shape service provision, infrastructure investment, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each offering unique competitive advantages and operational considerations. In the Americas, dense concentrations of biotechnology hubs and clinical development centers support rapid translational workflows and close provider-client interactions, while regulatory pathways and payer environments influence the emphasis on clinical pharmacology and data packages for North American sponsors. In Europe, Middle East & Africa, the regulatory mosaic and strong academic-research linkages encourage cross-border collaborations, multi-center studies, and harmonized assay validation to meet diverse jurisdictional expectations.

The Asia-Pacific region has expanded analytical capacity, driven by investment in laboratory infrastructure and a growing base of contract research capability; this growth supports cost-effective execution of high-volume bioanalysis and increasingly sophisticated work in biologics. Across regions, logistical considerations, sample transfer regulations, and local talent pools inform decisions about study design and outsourcing. Therefore, effective regional strategies blend proximity to clients, regulatory expertise, and supply chain resilience to deliver consistent, high-quality pharmacokinetic services while enabling global program execution and knowledge transfer.

Competitive dynamics favor providers that integrate advanced analytics, cross-disciplinary expertise, and client-centric commercial models to drive long-term partnerships

Leading companies in the pharmacokinetics services arena are evolving beyond transactional assay delivery to provide integrated scientific partnerships that span bioanalysis, modeling, and regulatory support. Successful firms differentiate through investments in platform automation, data integrity systems, and cross-functional teams that translate analytical output into actionable pharmacokinetic and pharmacodynamic interpretations. Strategic collaborations with instrument manufacturers and software vendors enhance analytical sensitivity and throughput, while internal development of standardized reporting templates accelerates regulatory submissions and client decision-making.

Moreover, companies are investing in talent development-combining analytical chemists, clinical pharmacologists, and modelers-to offer end-to-end program support. Commercially, flexible pricing models, bundled service offerings, and capacity guarantees are being used to align with client risk profiles and development timelines. Providers that demonstrate consistent quality, transparent audit readiness, and the ability to scale from early discovery to regulated clinical studies are most likely to retain long-term partnerships. In sum, the competitive landscape rewards organizations that pair scientific depth with operational excellence and client-centric service design.

Practical strategic priorities for service providers to strengthen scientific capabilities, operational resilience, and client-aligned commercial frameworks

Industry leaders should prioritize actionable changes that strengthen scientific capability, commercial resilience, and client alignment in the near term. First, investing in platform automation and robust bioanalytical workflows can reduce turnaround times and improve reproducibility, which is essential for maintaining competitiveness as therapeutic modalities diversify. Second, expanding modeling and simulation expertise within service teams enables providers to offer predictive insights that inform dose selection and trial design, thereby adding strategic value to client programs.

Third, diversifying supply chains and qualifying multiple reagent and equipment vendors mitigates risks from trade disruptions and tariff-related impacts. Fourth, developing flexible contracting frameworks and value-based pricing can align incentives with clients, particularly for biotechnology companies and sponsorship models that require iterative program adjustments. Finally, enhancing regulatory support services-including documentation readiness and clear modeling reports-helps clients navigate multi-jurisdictional submission requirements. Collectively, these initiatives will improve operational resilience, deepen scientific engagement, and position providers as indispensable partners in increasingly complex drug development pathways.

Transparent multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate pharmacokinetics service trends and implications

The research methodology underpinning this analysis integrates qualitative expert interviews, subject-matter literature review, and a structured assessment of technological and regulatory trends. Primary insights were derived from conversations with pharmacokinetic scientists, clinical pharmacologists, laboratory operations leaders, and procurement specialists, ensuring a multi-perspective understanding of capabilities and constraints. Secondary research included peer-reviewed publications, regulatory guidance documents, and recent technical white papers to capture advancements in bioanalytical instrumentation, modeling approaches, and assay validation practices.

Analytical synthesis emphasized cross-validation of themes across sources to identify consistent patterns rather than isolated observations. Where applicable, operational impacts were evaluated through scenario analysis to assess supply chain sensitivity and the implications of evolving regulatory expectations. Throughout, careful attention was paid to ensuring methodological transparency, documenting assumptions, and identifying areas where further empirical investigation would be valuable for specialized program planning or procurement decisions.

Concluding synthesis of strategic imperatives for providers to align scientific innovation, operational resilience, and client-focused delivery in pharmacokinetics services

In conclusion, pharmacokinetics services occupy a central role in translating molecular discovery into safe and efficacious clinical strategies, and the sector is adapting to technological, modality, and geopolitical pressures. Providers that invest in advanced bioanalytical platforms, expand modeling and simulation capabilities, and build resilient supply chains will be best positioned to meet the diverse needs of academic sponsors, biotechnology firms, contract research organizations, and large pharmaceutical companies. Furthermore, regional dynamics and tariff-related considerations underscore the importance of flexible sourcing and nearshoring strategies to preserve timelines and data quality.

Looking ahead, closer integration of analytical output with predictive modeling, regulatory-focused documentation, and client-centric contracting will define provider differentiation. By pursuing the actionable recommendations outlined earlier, stakeholders can reduce development risk, accelerate translational milestones, and align service delivery with strategic program objectives. Continued collaboration across scientific, operational, and commercial functions will be essential to sustain innovation and reliability within the pharmacokinetics services ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence models in early-phase pharmacokinetics modeling to optimize dose selection and predict human pharmacokinetics
  • 5.2. Rising demand for microdosing clinical trials using Accelerator Mass Spectrometry for enhanced safety and bioavailability profiling
  • 5.3. Expansion of custom in vitro human liver microsome testing services to support precision medicine and drug-drug interaction studies
  • 5.4. Adoption of organ-on-chip and microphysiological systems for physiologically relevant pharmacokinetics and toxicity assessments
  • 5.5. Growing utilization of population pharmacokinetic modeling software platforms in oncology drug development to streamline dose regimen design
  • 5.6. Shift toward outsourcing integrated PK/PD imaging and biomarker analytics to CROs for accelerated decision support in lead optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacokinetics Services Market, by Type

  • 8.1. Large Molecules Pharmacokinetics Services
  • 8.2. Small Molecules Pharmacokinetics Services

9. Pharmacokinetics Services Market, by Service Type

  • 9.1. In-Vitro
  • 9.2. In-Vivo

10. Pharmacokinetics Services Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Pharmacokinetics Services Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pharmacokinetics Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pharmacokinetics Services Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Absorption Systems LLC
    • 14.3.2. Allucent
    • 14.3.3. Aurigene Pharmaceutical Services Ltd.
    • 14.3.4. Certara
    • 14.3.5. Charles River Laboratories, Inc.
    • 14.3.6. Creative Bioarray
    • 14.3.7. Eurofins Scientific SE
    • 14.3.8. Evotec SE
    • 14.3.9. Frontage Laboratories, Inc.
    • 14.3.10. ICON PLC
    • 14.3.11. Laboratory Corporation of America Holdings
    • 14.3.12. LGC Limited by Cinven
    • 14.3.13. NUVISAN Pharma Holding GmbH
    • 14.3.14. Pacific BioLabs
    • 14.3.15. Parexel International (MA) Corporation
    • 14.3.16. Pfizer Inc.
    • 14.3.17. PPD Inc. by Thermo Fisher Scientific Inc.
    • 14.3.18. Premier Consulting
    • 14.3.19. Reaction Biology Corporation
    • 14.3.20. SGS SA
    • 14.3.21. Svar Life Science AB
    • 14.3.22. WuXi AppTec Co., Ltd.
    • 14.3.23. XenoTech by BioIVT
    • 14.3.24. Xyzagen

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACOKINETICS SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 63. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 76. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 84. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 93. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 97. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 109. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 116. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 134. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 135. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 151. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 158. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 159. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 219. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 243. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 260. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 267. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 268. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024